Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for disease. Employing its Transient Permeability Enhancer technology platform, Co. seeks to develop oral medications that are available as injections. Co.'s MYCAPSSA® (octreotide capsules) for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is an oral somatostatin analog. Co. is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the U.S. and develops and seeks regulatory approval of MYCAPSSA in the European Union. The CHMA stock yearly return is shown above.
The yearly return on the CHMA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CHMA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|